Skip to content

Hemoporphyrin Photodynamic therapy for Recurrent Respiratory Papillomatosis

Hemoporphyrin Photodynamic therapy for Recurrent Respiratory Papillomatosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086211
Enrollment
Unknown
Registered
2024-06-27
Start date
2024-07-03
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Respiratory Papillomatosis

Interventions

Photodynamic therapy group:Treatment consists of both surgery and systemically administered photodynamic therapy: Surgery: laryngeal lesions were excised from visible tumors using a braced laryngosco

Sponsors

The Affiliated BenQ Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)1-75; 2) Histopathologically confirmed recurrent respiratory papilloma;

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) History of photosensitizer or photosensitivity; 3) Intrapulmonary lesions; 4) Receipt of other adjuvant regimens such as bevacizumab within 3 months; 5) Having other pharyngeal disorders that interfere with treatment or follow-up; 6) Severe cardiac, hepatic or renal insufficiency or other contraindications to

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;Safety of photodynamic therapy;

Secondary

MeasureTime frame
Voice quality;Derkay Score;Structural damage to the vocal cords;

Countries

China

Contacts

Public ContactYuanyuan Lu

The Affiliated BenQ Hospital of Nanjing Medical University

luyy1234@outlook.com+86 135 1511 6267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026